Document:

EX-10.5

 EXHIBIT 10.5 

November 4, 2022 
 Bellevue Life Sciences Acquisition Corp.

 10900 NE 4th Street, Suite 2300 
 Bellevue, WA 98004 

Ladies and Gentlemen: 
 Bellevue Life Sciences
Acquisition Corp. (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act
of 1933, as amended (“Securities Act”), in connection with its initial public offering (“IPO”), pursuant to a registration statement on Form S-1 (“Registration
Statement”). 
 The undersigned, Bellevue Global Life Sciences Investors, LLC (the “Sponsor”), hereby commits that
it will purchase 390,000 units of the Company (“Placement Units”) upon the consummation of the IPO, each Placement Unit consisting of one share of common stock of the Company, $0.0001 par value (the “Common Stock”),
one warrant entitling the holder to purchase one share of Common Stock at a price of $11.50 per share, and one right entitling the holder thereof to receive one-tenth (1/10) of a share of Common Stock upon the consummation of an initial business
combination, at $10.00 per Placement Unit, for a purchase price of $3,900,000 (the “Placement Unit Purchase Price”). The Placement Unit Purchase Price will be paid by the Sponsor in the form of cash and/or the cancellation of
indebtedness owed by the Company to the Sponsor 
 At least twenty-four (24) hours prior to the pricing of the IPO, the Sponsor will
cause the Placement Unit Purchase Price to be delivered to a third-party acceptable to the Company and Sponsor (the “Custodian”) to be held in an escrow account acceptable to Chardan Capital Markets LLC (the
“Underwriter”). 
 The consummation of the purchase and issuance of the Placement Units shall occur simultaneously with the
consummation of the IPO. Simultaneously with or prior to the consummation of the IPO, the Company and the Underwriter shall instruct the Custodian to deposit a portion of the Placement Unit Purchase Price into the trust account as described in the
Registration Statement (the “Trust Account”). 
 The Placement Units will be identical to the units to be sold by the
Company in the IPO. Additionally, the Sponsor agrees: 
  

	 	•	 	 to vote the shares of Common Stock included in the Placement Units in favor of any proposed Business Combination;

  

	 	•	 	 not to propose, or vote in favor of, an amendment to the Company’s Amended and Restated Certificate of
Incorporation (the “Certificate of Incorporation”) that would affect the substance or timing of the Company’s obligation to redeem 100% of the Company’s shares of Common Stock sold in the IPO if the Company does not
complete an initial Business Combination within nine (9) months from the closing of the IPO (or any extended period approved by the stockholders of the Company, as applicable), unless the Company provides the holders of shares of Common Stock
underlying the units sold in the IPO with the opportunity to redeem their shares of Common Stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount of the
Trust Account, including interest earned on Trust Account and not previously released to the Company to pay the Company’s franchise and income taxes, divided by the number of then outstanding shares of Common Stock underlying the units sold in
the IPO; 

  

	 	•	 	 not to convert any shares of Common Stock included in the Placement Units into the right to receive cash from the
Trust Account in connection with a stockholder vote to approve either a Business Combination or an amendment to the provisions of the Certificate of Incorporation, and not to tender any shares of Common Stock included in the Placement Units in
connection with a tender offer conducted prior to the closing of a Business Combination; 

  

	 	•	 	 that the undersigned will not participate in any liquidation distribution with respect to the Placement Units or
any underlying securities (but will participate in liquidation distributions with respect to any units or shares of Common Stock purchased by the undersigned in the IPO or in the open market) if the Company fails to consummate a Business
Combination; 

  

	 	•	 	 that the Placement Units and underlying securities will not be transferable until
thirty-six (36) months after the consummation of a Business Combination except (i) to the Company’s pre-IPO stockholders, or to the

  

	 	 
Company’s officers, directors, advisors and employees, (ii) transfers to the Sponsor’s affiliates, including BCM Europe AG, or its members, (iii) to relatives and trusts for
estate planning purposes, (iv) by virtue of the laws of descent and distribution upon death, (v) pursuant to a qualified domestic relations order, (vi) by private sales made in connection with the consummation of a Business
Combination at prices no greater than the price at which the Placement Units were originally purchased hereunder or (vii) to the Company for cancellation in connection with the consummation of a Business Combination, in each case (except for
clause vii) where the transferee agrees to the terms of the transfer restrictions; 

  

	 	•	 	 The lock-up provisions set forth above will expire with respect to 50% of the Placement Units and underlying
securities in the event that the closing price of the Common Stock exceeds $12.50 for any 20 trading days within a 30-day trading day period following the consummation of the initial Business Combination; and

  

	 	•	 	 the Placement Units will include any additional terms or restrictions as is customary in other similarly
structured blank check company offerings or as may be reasonably required by the underwriters in the IPO in order to consummate the IPO, each of which will be set forth in the Registration Statement. 

The Sponsor acknowledges and agrees that any transferee of the Placement Units will execute agreements in form and substance typical for
transactions of this nature necessary to effectuate the foregoing agreements and obligations prior to the consummation of the transfer as are reasonably acceptable to the Company and the Sponsor, including but not limited to an insider letter. 

The Sponsor hereby represents and warrants that: 

(a)     it has been advised that the Placement Units have not been registered under the Securities Act; 

(b)     it will be acquiring the Placement Units for its account for investment purposes only; 

(c)     it has no present intention of selling or otherwise disposing of the Placement Units in violation of the
securities laws of the United States; 
 (d)     it is an “accredited investor” as defined by Rule 501 of
Regulation D promulgated under the Securities Act; 
 (e)     it has had both the opportunity to ask questions and
receive answers from the officers and directors of the Company and all persons acting on its behalf concerning the terms and conditions of the offer made hereunder; 

(f)     it is familiar with the proposed business, management, financial condition and affairs of the Company; 

(g)     it has full power, authority and legal capacity to execute and deliver this letter and any documents contemplated
herein or needed to consummate the transactions contemplated in this letter; and 
 (h)     this letter constitutes
its legal, valid and binding obligation, and is enforceable against it. 
 [Signature Page Follows] 

 EXHIBIT 10.5 
  

 This letter agreement shall be governed by and interpreted in accordance with the law of the
state of Delaware. This letter agreement constitutes the entire agreement between the Sponsor and the Company with respect to the purchase of the Placement Units, and supersedes all prior and contemporaneous understandings, agreements,
representations and warranties, both written and oral, with respect to the same.
  

			
	Very truly yours,
	
	BELLEVUE GLOBAL LIFE SCIENCES INVESTORS, LLC
	By: Bellevue Capital Management LLC,
	Its Manager
	
	 /s/ Kuk Hyoun Hwang

	Name:	 	Kuk Hyoun Hwang
	Title:	 	Managing Member

  

	
	ACCEPTED AND AGREED:
	
	BELLEVUE LIFE SCIENCES
	ACQUISITION CORP.
	
	 /s/ Kuk Hyoun Hwang

	Name:     Kuk Hyoun Hwang
	Title:       Chief Executive OfficerEX-10.7

 EXHIBIT 10.7 

Bellevue Life Sciences Acquisition Corp. 

251 Little Falls Drive 
 Wilmington,
New Castle County 
 Delaware 19808 

November 4, 2022 
 Bellevue Capital
Management, LLC 
 10900 NE 4th Street, 2300 

Bellevue, WA 98004 
 Re: Administrative Services Agreement 

Ladies and Gentlemen: 
 This letter agreement by
and between Bellevue Life Sciences Acquisition Corp. (the “Company”) and Bellevue Capital Management, LLC (“BCM”), an affiliate of our sponsor, Bellevue Global Life Sciences Investors LLC, dated as of the date hereof, will
confirm our agreement that, commencing on the date the securities of the Company are first listed on NASDAQ (the “Listing Date”), pursuant to a Registration Statement on Form S-1 and
prospectus filed with the Securities and Exchange Commission (the “Registration Statement”) and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation (in each
case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”): 
  

	 	(i)	 BCM shall make available to the Company, at the following three business addresses: 

 

	 	1	 10900 NE 4th Street, 2300, Bellevue, WA 98004

  

	 	2	 37 Gukjegeumyung-ro 2-gil,
#2204, Seoul, 07327 Korea 

  

	 	3	 Vulkanstrasse 110b/82, 8048 Zürich, Switzerland 

certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. In exchange therefor, the Company
shall pay BCM the sum of $7,500 per month on the Listing Date and continuing monthly thereafter until the Termination Date; and 
 (ii) BCM
hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind as a result of, or arising out of, this letter agreement (each, a “Claim”) in or to, and any and all right to seek payment of any amounts
due to it out of, the trust account established for the benefit of the public stockholders of the Company and into which substantially all of the proceeds of the Company’s initial public offering will be deposited (the “Trust
Account”), and hereby irrevocably waives any Claim it may have in the future, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in the Trust Account, and further agrees not to seek
recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever. 

This letter agreement constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes
all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. 

This letter agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by the
parties hereto. 
 No party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without
the prior written approval of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. 

 This letter agreement constitutes the entire relationship of the parties hereto, and any
litigation between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York, without giving effect to its choice of
laws principles. 
  

			
	Very truly yours,
	
	Bellevue Life Sciences Acquisition Corp.
		
	By:	 	 /s/ Kuk Hyoun Hwang

	Name:	 	Hwang, Kuk Hyoun
	Title:	 	Chief Executive Officer

  

			
	AGREED TO AND ACCEPTED BY:
	
	Bellevue Capital Management, LLC
		
	By:	 	 /s/ Kuk Hyoun Hwang

	Name:	 	Hwang, Kuk Hyoun
	Title:	 	Managing Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]